The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...

Switching UC treatments while managing a career and home life can be a major challenge. Here’s how to navigate work logistics, family communication, and side effects.

For people with UC, ‘feeling better’ is just the start. Learn why tissue-level (histological) healing is becoming the new ...

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by recurrent intestinal inflammation, abdominal ...

An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

Credit: Getty Images What have we learned in recent years about the safety and efficacy of different biologics for the treatment of ulcerative colitis? Ulcerative colitis (UC) is a condition with a ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

Aminosalicylate (5-ASA) therapy is often the first treatment option for patients presenting with mild to moderate ulcerative colitis (UC). Symptom improvements can be observed within 2 to 4 weeks ...

A 52-week phase 3 clinical trial of Skyrizi, or risankizumab — a drug initially approved to treat Crohn’s disease, psoriatic arthritis and psoriasis — was shown to also achieve clinical remission in ...

(MENAFN- EIN Presswire) EINPresswire/ -- Ulcerative Colitis Market to Surpass $26 billion in 2030. Within the broader Healthcare Services industry, which is expected to be $10,759 billion by 2030, the ...